The proposed, Finnish, ProScreen trial

A group of Finnish researchers have planned a new trial to investigate whether population-based screening for prostate cancer is justifiable if a mortality benefit can be proven with a substantial reduction in rates of over-treatment. … READ MORE …

An update on “screening” for prostate cancer: four perspectives

To quote the abstract of the paper discussed below, the use of the PSA test to screen for risk of prostate cancer “in men at normal risk of prostate cancer is one of the most contested issues in cancer screening.” No! Really? … READ MORE …

It’s not “as big a deal as you might think”

What isn’t as big a deal as we might think? According to The New York Times this morning, the US Preventive Services Task Force’s new recommendations about prostate cancer screening. … READ MORE …

Prostate cancer detection and associated risk management

Dr. Michael Barry has been a long-time advocate for caution in the appropriate use of PSA testing and for awareness of the risks of over-treatment of low-risk forms of prostate cancer. … READ MORE …

Feedback to USPSTF on new, draft recommendations on PSA screening

As many readers will be aware, the U.S. Preventive Services Task Force (USPSTF) recently issued new, draft guidance on the role of testing for risk of prostate cancer, and most particularly on the use of PSA testing in men of 55 years and older. All public comment on the proposed new draft recommendations is due on or before May 8 upcoming. … READ MORE …

More about screening … current and future issues

So there are two new articles recently published on the prostate cancer screening issue. One deals with the numbers of men  in America who seem to be getting screened today. The other addresses whether there should be different guidance on prostate cancer screening for African Americans as opposed to “the rest of us” (Caucasians, Hispanics, and “white” Americans). … READ MORE …

What The Lancet thinks about the new USPSTF screening guidelines

There is a thoughtful editorial in this week’s issue of The Lancet on the new, draft guidelines on PSA-based screening for prostate cancer issued recently by the U.S. Preventive Services Task Force (USPSTF). It is an editorial that we encourage our readers to look at for themselves.